肿瘤血液患者发热性中性粒细胞减少症首周持续输注β-内酰胺类药物的积极PK/PD靶标达成可能性
这项为期1年的前瞻性观察研究纳入256例接受持续输注β-内酰胺类药物治疗的成人肿瘤血液患者,在治疗第3至7天测定稳态血药浓度。靶向治疗者积极PK/PD靶标达成率为85.4%,经验性治疗者为57.5%;增强肾清除率、男性和年龄<65岁独立预测靶标未达成。
要点
- 持续输注β-内酰胺类药物在靶向治疗时积极PK/PD靶标达成率高于经验性治疗。
- 增强肾清除率是药物暴露不足的主要决定因素。
- 建议对此类高危患者进行治疗药物监测以优化给药。
核心结论
- 持续输注β-内酰胺类药物在肿瘤血液患者靶向治疗期间可可靠达到积极PK/PD靶标,但经验性治疗期间不能。
- 增强肾清除率是药物暴露不足的主要决定因素,支持使用治疗药物监测优化剂量。
研究设计与样本
- 前瞻性观察性研究,为期1年,纳入256例接受持续输注β-内酰胺类药物经验性或靶向治疗的成人肿瘤血液患者。
- 在治疗第3至7天测定稳态血浆浓度,积极PK/PD靶标定义为游离稳态浓度与MIC(或临床折点)比值≥4,β-内酰胺/β-内酰胺酶抑制剂组合采用联合PK/PD靶标。
主要发现
- 靶向治疗患者中积极PK/PD靶标达成率为85.4%,经验性治疗患者为57.5%。
- 靶标未达成最常见于哌拉西林/他唑巴坦和头孢他啶/阿维巴坦。
- 增强肾清除率(OR 12.29,P < 0.001)、男性(OR 3.79,P < 0.001)和年龄<65岁(OR 2.40,P = 0.025)独立预测靶标未达成。
- 靶向治疗和美罗培南使用与更高的靶标达成相关。
关键数值与推荐
- 积极PK/PD靶标:游离稳态浓度与MIC(或临床折点)比值≥4;β-内酰胺/β-内酰胺酶抑制剂组合采用联合PK/PD靶标。
- 靶向治疗者靶标达成率85.4%,经验性治疗者57.5%。
- 增强肾清除率OR 12.29(P < 0.001),男性OR 3.79(P < 0.001),年龄<65岁OR 2.40(P = 0.025)。
临床怎么用
- 对肿瘤血液合并发热性中性粒细胞减少症患者使用持续输注β-内酰胺类药物时,应关注经验性治疗下靶标达成率较低。
- 对增强肾清除率、男性或年龄<65岁患者,考虑进行治疗药物监测以优化给药。
局限性
- 单中心研究,结果外推需谨慎。
- 仅评估治疗第一周内稳态浓度,未报告长期临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Onco-haematological patients with febrile neutropenia are at high risk of severe infections caused by multidrug-resistant pathogens. Continuous infusion (CI) of beta-lactams may improve pharmacokinetic/pharmacodynamic (PK/PD) target attainment, yet evidence in this population remains limited. OBJECTIVES: To evaluate the likelihood of achieving an aggressive PK/PD target with CI beta-lactams during the first week of therapy in onco-haematological patients and to identify predictors of target non-attainment. METHODS: This prospective observational study enrolled adult onco-haematological patients receiving CI beta-lactams for empirical or targeted treatment over a 1-year period. Steady-state plasma concentrations were measured between days 3 and 7. The aggressive PK/PD target was defined as a free steady-state concentration-to-MIC (or clinical breakpoint) ratio ≥4; for beta-lactam/beta-lactamase inhibitor combinations, a joint PK/PD target was applied. Multivariate logistic regression analysis identified factors associated with target attainment. RESULTS: A total of 256 patients were included, 82 of whom (32.1%) received targeted therapy. Aggressive PK/PD target attainment was achieved in 85.4% of patients undergoing targeted treatment, compared with 57.5% of those treated empirically. Target non-attainment occurred most frequently with piperacillin/tazobactam and ceftazidime/avibactam. Augmented renal clearance (OR 12.29, P < 0.001), male sex (OR 3.79, P < 0.001) and age <65 years (OR 2.40, P = 0.025) independently predicted target non-attainment, whereas targeted therapy and meropenem use were associated with a higher attainment. CONCLUSIONS: CI beta-lactams reliably achieve aggressive PK/PD targets during targeted therapy but not during empirical treatment in onco-haematological patients. Augmented renal clearance is a major determinant of underexposure, supporting the use of therapeutic drug monitoring to optimize dosing in this high-risk population.
引用
- Cojutti PG, Toschi A, Pasquini Z, et al. Likelihood of aggressive PK/PD target attainment of continuous-infusion beta-lactams during the first week of treatment of febrile neutropenia: findings from a 1-year prospective, monocentric study in onco-haematological patients. J Antimicrob Chemother. 2026. PMID: 42234486. doi:10.1093/jac/dkag183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。